PeerView Clinical Pharmacology CME/CNE/CPE Video
by PVI, PeerView Institute for Medical Education
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇳🇬NG · Science#763K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
900 to 3K🎙 Daily cadence·932 episodes·Last published 3w ago - Monthly Reach
Unique listeners across all episodes (30 days)
3K to 10K🇳🇬100% - Active Followers
Loyal subscribers who consistently listen
1.2K to 4K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 20 epsHosts
Not detected.
Recent guests
Recent episodes
Andrew Kuykendall, MD - Ironing Out the Challenges of PV: Spotlight on Targeting the Hepcidin Pathway for Addressing Unmet Needs and Enhancing Patient Outcomes
Jun 5, 2026
31m 51s
Brendon M. Stiles, MD - The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies
Jun 4, 2026
1h 05m 50s
Adam Friedman, MD, FAAD - Wheals of Fortune: Chronic Spontaneous Urticaria Challenges and the Road to Resolution
May 29, 2026
55m 16s
Anna Chodos, MD, MPH - Getting Ahead of Cognitive Decline—Applying Patient-Centered Strategies to Assess and Reduce Dementia Risk in Primary Care: An AI-Guided Case Simulation Activity
May 29, 2026
46m 16s
Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy
May 29, 2026
59m 51s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/5/26 | Andrew Kuykendall, MD - Ironing Out the Challenges of PV: Spotlight on Targeting the Hepcidin Pathway for Addressing Unmet Needs and Enhancing Patient Outcomes✨ | Hepcidin PathwayPatient Outcomes+3 | Andrew Kuykendall, MD | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education+2 | — | Polycythemia VeraHepcidin+5 | Takeda Pharmaceuticals U.S.A., Inc. | 31m 51s | |
| 6/4/26 | Brendon M. Stiles, MD - The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies✨ | immunotherapyNSCLC+4 | Brendon M. Stiles, MD | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education+2 | Rahway, NJ, USA | immunotherapyNSCLC+5 | AstraZeneca | 1h 05m 50s | |
| 5/29/26 | Adam Friedman, MD, FAAD - Wheals of Fortune: Chronic Spontaneous Urticaria Challenges and the Road to Resolution✨ | Chronic Spontaneous UrticariaHealthcare Education+3 | Adam Friedman, MD, FAAD | University of CincinnatiAccreditation Council for Continuing Medical Education+1 | — | Chronic Spontaneous UrticariaCME+3 | Novartis Pharmaceuticals Corporation | 55m 16s | |
| 5/29/26 | Anna Chodos, MD, MPH - Getting Ahead of Cognitive Decline—Applying Patient-Centered Strategies to Assess and Reduce Dementia Risk in Primary Care: An AI-Guided Case Simulation Activity✨ | cognitive declinedementia risk+4 | Anna Chodos, MD, MPH | PVI, PeerView Institute for Medical EducationBrightFocus Foundation+3 | — | cognitive declinedementia+6 | Lilly | 46m 16s | |
| 5/29/26 | Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy✨ | Oncology NursingImmunotherapy+3 | Charise GleasonBeth Faiman | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education+2 | — | RRMMOncology+4 | GSK | 59m 51s | |
| 5/29/26 | Anita Afzali, MD, MPH, MHCM, FACG, AGAF / Jessica R. Allegretti, MD, MPH, FACG, AGAF / Millie D. Long, MD, MPH - At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition✨ | InflammationFibrosis+4 | Anita Afzali, MD, MPH, MHCM, FACG, AGAFJessica R. Allegretti, MD, MPH, FACG, AGAF+1 | PVI, PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | inflammationfibrosis+4 | Merck & Co., Inc. | 1h 10m 58s | |
| 5/29/26 | Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models✨ | NF1-PNMEK Inhibition+3 | Amy E. Armstrong, MDAngela Hirbe, MD, PhD | PVI, PeerView Institute for Medical EducationNeurofibromatosis Network | — | NF1-PNMEK Inhibition+4 | Alexion | 1h 05m 17s | |
| 5/29/26 | Luke Maese, DO, Rachel Rau, MD - ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients✨ | Asparaginase ExposurePersonalized Treatment+3 | Luke Maese, DORachel Rau, MD | PVI, PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | AsparaginasePediatric Patients+6 | Jazz Pharmaceuticals | 48m 37s | |
| 5/29/26 | Bhavana Pothuri, MD, MS / Premal Thaker, MD, MS - Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans✨ | advanced ovarian cancerpersonalized treatment plans+3 | Bhavana Pothuri, MD, MSPremal Thaker, MD, MS | PVI, PeerView Institute for Medical EducationNational Ovarian Cancer Coalition+3 | — | ovarian cancertargeted therapy+3 | GSK | 51m 15s | |
| 5/29/26 | Jaume Capdevila, MD, PhD - Propelling Modern Interventions in Neuroendocrine Carcinoma: Multidisciplinary Principles to Effectively Implement Emerging DLL3-Directed BiTE Therapy in Community Settings✨ | Neuroendocrine CarcinomaDLL3-Directed BiTE Therapy+3 | Jaume Capdevila, MD, PhD | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education+2 | — | Neuroendocrine CarcinomaDLL3-Directed BiTE Therapy+3 | Boehringer Ingelheim Pharmaceuticals, Inc. | 54m 53s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/7/26 | Christie M. Ballantyne, MD, FACP, FACC - Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets✨ | PCSK9 InhibitionLDL-C Targets+3 | Christie M. Ballantyne, MD, FACP, FACC | PVI, PeerView Institute for Medical EducationThe Mended Hearts, Inc. | Rahway, NJ, USA | PCSK9LDL-C+5 | Merck & Co., Inc. | 1h 22m 52s | |
| 5/7/26 | Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH, Richard Dang, PharmD - RSV in Focus: Pharmacists Driving Vaccine Access, Confidence, and Education✨ | RSVvaccine access+3 | Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPHRichard Dang, PharmD | PVI, PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | RSVvaccine+5 | GSK | 59m 54s | |
| 5/7/26 | David Sabatino, PharmD, BCOP / Marie E. Sirek, PharmD, BCACP, CPP - B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers✨ | Pharmacist PrinciplesBTK Targeting+4 | David Sabatino, PharmD, BCOPMarie E. Sirek, PharmD, BCACP, CPP | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education+2 | — | BTK TargetingChronic Lymphocytic Leukemia+4 | AstraZeneca | 57m 33s | |
| 5/7/26 | Unpacking Parkinson's Disease Psychosis: Rapid Detection and Management in Long-Term Care - Unpacking Parkinson's Disease Psychosis: Rapid Detection and Management in Long-Term Care✨ | Parkinson's DiseasePsychosis+3 | — | PVI, PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | Parkinson's Diseasepsychosis+5 | ACADIA Pharmaceuticals Inc. | 56m 47s | |
| 5/7/26 | Jay H. Shubrook, DO, FAAFP, FACOFP - Unlocking the Potential of Incretin-Based Therapies in T2D: Comprehensive Primary Care Strategies for Cardiometabolic Health✨ | incretin-based therapiestype 2 diabetes+3 | Jay H. Shubrook, DO, FAAFP, FACOFP | PVI, PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | incretintype 2 diabetes+6 | Lilly | 1h 25m 04s | |
| 5/7/26 | J. Andrew Berkowski, MD, FAASM - Transforming Restless Legs Syndrome Management: Bridging Treatment Gaps With Updated Guidelines and Device-Integrated Solutions✨ | Restless Legs SyndromeTreatment Guidelines+3 | J. Andrew Berkowski, MD, FAASM | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education+2 | — | Restless Legs Syndrometreatment gaps+5 | Noctrix Health, Inc. | 46m 37s | |
| 5/7/26 | Tiba Al Sagheer, PharmD, BCOP, BCACP, Amanda Yepes, PharmD, BCOP - Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation✨ | NHLCAR-T Therapy+4 | Tiba Al Sagheer, PharmD, BCOP, BCACPAmanda Yepes, PharmD, BCOP | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | NHLCAR-T Therapy+5 | Bristol Myers Squibb | 1h 00m 30s | |
| 5/7/26 | April W. Armstrong, MD, MPH - A New Era in Psoriasis Care With Oral IL-23 Inhibitors✨ | Psoriasis careOral IL-23 inhibitors+3 | April W. Armstrong, MD, MPH | PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education+2 | — | psoriasisIL-23 inhibitors+3 | Johnson & Johnson | 33m 41s | |
| 5/7/26 | Professor Christopher Chen, Professor Atsushi Iwata, MD, PhD - Strategies for Appropriate Assessment and Use of APOE Status in Alzheimer’s Disease: Clinical Care in the Asia-Pacific Region✨ | Alzheimer's DiseaseAPOE Status+4 | Professor Christopher ChenProfessor Atsushi Iwata, MD, PhD | PVI, PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | APOEAlzheimer's Disease+4 | Lilly | 45m 04s | |
| 4/28/26 | Justin Arnall, PharmD, FCCP, BCOP / Anthony J. Perissinotti, PharmD, BCOP - Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy✨ | myelofibrosispharmacist leadership+3 | Justin Arnall, PharmD, FCCP, BCOPAnthony J. Perissinotti, PharmD, BCOP | PVI, PeerView Institute for Medical EducationAccreditation Council for Continuing Medical Education (ACCME)+2 | — | myelofibrosisJAK inhibitors+3 | GSK | 57m 16s | |
| 2/20/24 | Erika Hamilton, MD - Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC | This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KBV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 17, 2025.Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).Faculty/PlannerKomal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.Faculty/PlannerProfessor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below. | — | ||||||
| 2/13/24 | Erin X. Barrett (Wei), MD - Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care | This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/MPM865. CME/MOC/NCPD/AAPA credit will be available until February 6, 2025.Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerErin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.Co-Chair/PlannerDavid Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below. | — | ||||||
Showing 22 of 2
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.